Indo Us Biotech profit and loss

Latest FY26

Revenue: ₹110cr+6.4% on FY25
EBITDA: ₹17.0cr−10.2% on FY25
Net profit: ₹13.1cr−19.3% on FY25
EPS: ₹6.54−19.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	96.9	110	104
	0.2	0.1	0.2
	97.1	110	104
	60.2	78.3	71.0
	40.2	31.2	20.5
	−25.0	−29.2	−18.9
	1.4	1.4	1.1
	2.9	2.2	1.5
	1.0	0.9	1.1
	11.3	11.7	11.2
	92.1	96.6	87.5
	8.7	17.0	18.9
	7.7	16.1	17.8
Profit
	5.0	13.9	16.5
	5.0	13.9	16.5
	0.5	0.6	0.3
	0.2	0.2	−0.1
	0.6	0.8	0.3
	4.3	13.1	16.3
	4.3	13.1	16.3
	−0.0	0.0	0.0
	4.3	13.1	16.3
Per share
	₹2.15	₹6.54	₹8.12
	₹2.15	₹6.54	₹8.12
Other comprehensive income — detail
	−0.0	0.0	0.0
	0.0	−0.0	−0.0
	−0.0	0.0	0.0
Per share — as-filed variants
	₹2.15	₹6.54	₹8.12
	₹2.15	₹6.54	₹8.12
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	21.5	30.2	31.2
	22.2%	27.3%	30.0%
Adjusted (ex-exceptional items) — derived
	5.0	13.9	16.5
	4.3	13.1	16.3
	₹2.15	₹6.54	₹8.12

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail

Annual Quarterly₹ CrorePeersKOHINOOR NATHBIOGEN AGRITECH SARVESHWAR SUKHJITS REGAAL BSHSL GULPOLYMcap ₹157 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	103.8	110.4	96.9
Other Income	0.2	0.1	0.2
Total Income	104.0	110.5	97.1
Expenses
+ Cost of Materials Consumed	71.0	78.3	60.2
+ Purchases of Stock-in-Trade	20.5	31.2	40.2
+ Changes in Inventories	-18.9	-29.2	-25.0
+ Employee Benefit Expense	1.1	1.4	1.4
+ Finance Costs	1.5	2.2	2.9
+ Depreciation & Amortisation	1.1	0.9	1.0
+ Other Expenses	11.2	11.7	11.3
Total Expenses	87.5	96.6	92.1
EBITDA	18.9	17.0	8.7
EBIT	17.8	16.1	7.7
Profit
PBT before Exceptional Items	16.5	13.9	5.0
Pretax Income	16.5	13.9	5.0
+ Current Tax	0.3	0.6	0.5
+ Deferred Tax	-0.1	0.2	0.2
Tax Expense	0.3	0.8	0.6
Net Income	16.3	13.1	4.3
+ Net Income — Continuing Ops	16.3	13.1	4.3
+ Other Comprehensive Income	0.0	0.0	-0.0
Total Comprehensive Income	16.3	13.1	4.3
Per Share
Basic EPS	8.12	6.54	2.15
Diluted EPS	8.12	6.54	2.15
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.0	0.0	-0.0
+ Tax on Items NOT to be Reclassified	-0.0	-0.0	0.0
+ Tax on Items to be Reclassified	0.0	0.0	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.12	6.54	2.15
Diluted EPS — Continuing Operations	8.12	6.54	2.15
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	31.2	30.2	21.5
Gross Margin %	30.03	27.32	22.15
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	16.5	13.9	5.0
Net Income Adj (tax-effected)	16.3	13.1	4.3
EPS Adj	8.12	6.54	2.15
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00
Paid Up Equity Capital	20.1	20.1	20.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.